The applicability of β-amyloid peptide (Aβ) positron emission tomography (PET) as a biomarker in clinical settings to aid in selection of individuals at preclinical and prodromal Alzheimer disease (AD) will depend on the practicality of PET image analysis. In this context, visual-based Aβ PET assessment seems to be the most feasible approach.
I ncreased brain β-amyloid peptide (Aβ) seen with positron emission tomography (PET) and decreased Aβ1-42 measured in cerebrospinal fluid (CSF) allow in vivo detection of Aβ, with substantial agreement. [1] [2] [3] [4] These biomarkers have therefore been proposed as indicators of Alzheimer disease (AD) neuropathology, aiding the selection and monitoring of individuals with mild cognitive impairment (MCI) due to AD or prodromal AD in clinical trials. 5, 6 In MCI, Aβ load assessment may be additionally useful for prognostication since Aβ PET positivity predicts a higher risk of cognitive decline and AD conversion. [7] [8] [9] [10] [11] [12] [13] [14] [15] With the exception of a few studies of relatively small samples, 7, 13, 16 most MCI studies evaluating the prognostic value of Aβ PET 8, 9, 11, 14, 17 and the agreement between Aβ PET with Aβ CSF markers [2] [3] [4] have used semiquantitative image assessments of standardized uptake value ratios (SUVRs). Although visual Aβ PET rating is relatively simple and is the standard in clinical practice, there is a lack of knowledge about its significance for prognostication in large MCI cohorts and its agreement with CSF Aβ1-42 data and more quantitative PET measures. In terms of participant selection for clinical trials, further research is needed to evaluate whether MCI due to AD could be equivalently identified by visual PET ratings.
The goals of our study were to investigate the concordance between visual and quantitative Aβ PET analysis and evaluate how each of those image assessments agrees with CSF Aβ1-42 data in MCI. We further aimed to examine the effect of visual and quantitative image categorization as Aβ PET negative or positive to predict longitudinal cognitive function and AD conversion risk. Our methodologic design intentionally corresponds to the setting of large clinical trials including a large MCI sample derived from various sites or centers using different PET scanners and performing Aβ imaging with florbetapir F 18 [ 18 F], a tracer approved for clinical use by the US Food and Drug Administration and European Medicines Agency.
Methods

Participants
Our analysis was performed on participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI), a multisite study supported by the National Institutes of Health, private pharmaceutical companies, and nonprofit organizations, with a goal of using multimodal imaging, CSF, and cognitive measurements in elderly controls as well as patients with MCI or AD to standardize and validate biomarkers in AD clinical trials. Additional methodologic information on participants, image acquisition, CSF, and data analysis, is provided in eAppendix 2 in the Supplement. All participants provided written informed consent. The institutional review board of each participating institution approved this study. Provision of financial compensation depended on the local policies of the individual study sites. The study was performed from September 21, 2010, to August 11, 2014 ; data analysis was conducted from September 21, 2014 
Results
Participants
Descriptive statistics of the participants are given in Table 1 . The overall conversion rate was 15.2% over a mean of 1.6 years; the rates for EMCI and LMCI were 5.5% and 32.4%, respectively. Nonconverters and converters differed on baseline cognition and several biomarkers (eAppendix 2 in the Supplement). cases are demonstrated in Figure 1 ; the findings of a detailed visual inspection of all 53 discordant cases are given in eAppendix 2 in the Supplement. Demographic data, baseline cognition, and biomarkers did not differ significantly between participants with discordant and concordant visual and SUVR analysis (eAppendix 2 in the Supplement). Considering all 125 cases rated by both readers, interrater reliability was substantial (κ = 0.76). For those 53 participants with discordant visual (reader 1) and quantitative Aβ PET analysis, interreader agreement was only moderate (κ = 0.44), but it was very high for the remaining 72 individuals with concordant visual (reader 1) and SUVR florbetapir results (κ = 0.92). Table 2 ). An approximately 6-fold to 9-fold greater conversion hazard for a visual [ (Table 2) . Although positive baseline SUVR data revealed a slightly lower conversion hazard than did the visual results, hazard ratios did not differ between quantitative and visual [ 18 F] florbetapir PET analysis, as indicated by the ratios' 95% CI overlap (Table 2 ).
Agreement Between Aβ Biomarkers
Prediction of Longitudinal Cognitive Function and Conversion From MCI to AD
Discussion
We found substantial agreement between visual Aβ PET, quantitative Aβ PET, and CSF Aβ1-42 analysis in patients with MCI.
In approximately 10% of all cases, agreement between visual and quantitative [ 18 F] florbetapir analysis was poor, as was agreement between both readers and between PET and CSF data. Furthermore, both visual and quantitative Aβ PET assessment performed similarly in predicting longitudinal cognitive function and MCI to AD conversion.
Concordance between visual and quantitative image analysis was lower than that reported in a study 26 that included patients with AD. Similarly, acquisition of data in a single center, as opposed to this multicenter study, appears to result in a higher concordance between qualitative and SUVR measures (κ values up to 0.96). 13, 26 In addition to its multicenter approach, our study differs from previous MCI investigations that compared visual and quantitative PET analysis by (1) the use of [ ; (2) the inclusion of individuals with EMCI; (3) the application of a less conservative SUVR threshold 13 ; and (4) the examination of a much larger and likely more heterogeneous MCI sample. 7, 13, 26, 27 All of those aspects may have contributed to the somewhat lower concordance between visual readings and SUVRs in the present study.
In contrast, our interrater reliability (κ = 0.92) was somewhat higher than that in another visual MCI PET study (κ = 0.46-0.86). 7 However, this very high interreader reliability was generated from a subsample of cases that already agreed between visual (reader 1) and SUVR analysis; therefore, it is likely to be biased toward higher concordance. When including all 125 cases rated by both readers (as described in the Methods section), interrater reliability was somewhat lower but still substantial (κ = 0.76). Because the subsample of 125 cases read by rater 2 specifically included the 53 participants with discordant qualitative (reader 1) and quantitative data, corresponding interrater agreement was biased toward lower concordance.
To have an objective, independent criterion, we considered CSF as a reference standard and found that visual readings resulted in lower sensitivity and higher specificity compared with SUVR analysis. The use of CSF as an external reference allowed us to compare visual and SUVR analysis with a third measure. Addition of this measure does not suggest that CSF Aβ should be considered as the reference standard or that our approach refers to general recommendations, especially since CSF and PET Aβ represent different aspects of cerebral Aβ pathology. 28, 29 In fact, it has been proposed that CSF Aβ reduction indicates earlier stages of abnormality and increased Aβ PET retention reflects later stages of cerebral Aβ and AD pathology. 30 In terms of its high specificity but slightly lower sensitivity, visual analysis may be useful for selection of individuals with MCI for participation in intervention trials aiming to avoid the treatment of true-negatives. Compared with SUVRs, visual readings may be less useful for clinical trials aiming to capture as many Aβ-positive cases as possible, especially those at very early Aβ stages (eg, EMCI). Continuous SUVR measures Amyloid-positive baseline PET predicted approximately 4-fold to 9-fold higher conversion risk even after adjustment for positive APOE ε4 carrier status, an abnormal concurrent FDG-PET scan, and 1-score worsening of a lower baseline ADAS-cog score. An Aβ-positive PET scan thus adds considerable predictive value even in the presence of genetic and cognitive status, as well as in the absence of additional biomarkers. Moreover, our data emphasize that the frequency of Aβ positivity and conversion rates increase with severity of cognitive symptoms. 11 Depending on the method used for Aβ load assessment, we found that 40.6% to 59.5% and 63.4% to 72.2% of EMCI and LMCI cases, respectively, were Aβ positive and that 5.5% and 32.4% of participants with EMCI and LMCI, respectively, converted to AD within 1.5 years. In general, all results were comparable between the qualitative and quantitative analyses.
Conclusions
Our findings suggest that visual readings and SUVRs are equivalent in their assignment of negative or positive Aβ status in MCI. Even including genetic, cognitive, and FDG status, qualitative and quantitative PET analysis adds significant value for clinical course prognostication. Our data thus support the applicability of a simpler case inclusion algorithm that may facilitate case selection in trials evaluating MCI due to AD.
